Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Filgrastim - Amgen/Roche

Drug Profile

Filgrastim - Amgen/Roche

Alternative Names: G-CSF; Gracinᵀᴹ; Gran; Granulocyte colony-stimulating factor - Amgen; Granulokine; Grasinᵀᴹ; KRN 8601; Meograstim; Neupogen; Nupen

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kirin-Amgen
  • Developer Amgen; Apricus Biosciences; Bristol-Myers Squibb; GSK; Kirin Holdings Company; Kirin-Amgen; University of Washington
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
  • Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chemotherapy-induced damage; Neutropenia; Radiation injuries
  • No development reported Breast cancer

Most Recent Events

  • 15 Mar 2021 Filgrastim licensed to Clinigen for distribution in Africa and Asia
  • 06 Jan 2020 No development reported - Phase-I/II for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (SC) (NCT00041470)
  • 15 Nov 2019 Kyowa Kirin completes a phase II trial in Neutropenia in South Korea (NCT02685111)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top